Biotech Values

[Titan V]

PD-L1 as a Biomarker Predictive of Response to Checkpoint Inhibition in Lung Cancer
https://shar.es/1O5gjd

The advent of immunotherapy has changed the treatment landscape of many solid tumors, amongst which, non-small cell lung cancer (NSCLC). While reports of impressive efficacy and favorable side effect profiles are numerous, little is known about which patients should be selected to receive immunotherapy. The activation of the programmed death-1 (PD-1) and programmed-death ligand-1 (PD-L1) axis is known to cause tumor regression via T-cell activation. The presence and level of PD-L1 in tumor tissues has been postulated by many to serve as a biomarker, predictive of response to checkpoint inhibition. Here, we review the data as it relates to PD-L1 expression in lung cancer and its use as a predictive biomarker.